Daniel L. Hertz received a PharmD from the Ernest Mario School of Pharmacy at Rutgers University in 2008 and a PhD in Pharmaceutical Sciences from the UNC Eshelman School of Pharmacy in 2013. He has always had a passion for cancer research. During his graduate program, Dr. Hertz worked with Howard McLeod, who introduced him to the field of cancer pharmacogenetics. Dr. Hertz's dissertation research focused on discovery and validation of pharmacogenetic predictors of taxane-induced neuropathy. After receiving his PhD, Dr. Hertz joined the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy, where he is currently an Associate Professor.

Dr. Hertz's current research focuses on developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. His R37 uses data and biosamples collected on the prospective SWOG S1714 clinical trial to discover biomarkers (e.g., kinetics, genetics, metabolomics, nutrients) of taxane-induced peripheral neuropathy. These biomarkers could be used to identify patients at higher risk of neuropathy, in whom personalized treatment approaches or experimental preventive strategies can be investigated. This may lead to an improved standard of care that avoids long-term debilitating toxicity and improves treatment effectiveness.